MSK
LIVE

Serial Number

99281840

Owner

Memorial Sloan-Kettering Cancer Center

Attorney

Natasha Reed

First Use Date

Dec 31, 1988

Filing Date

Jul 14, 2025

Add to watchlist:

No watchlists yet
View on USPTO

MSK Trademark

Serial Number: 99281840

MSK is a trademark filed by Memorial Sloan-Kettering Cancer Center on July 14, 2025. The trademark is classified under Class 36 (Insurance & Financial), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Memorial Sloan-Kettering Cancer Center

1275 York Avenue
New York, NY 10065

Entity Type: 03

Trademark Details

Filing Date

July 14, 2025

Registration Date

Not Registered

First Use Anywhere

December 31, 1988

First Use in Commerce

December 31, 1988

Goods & Services

Educational services, namely, training clinicians and healthcare providers in analysis of clinical data utilizing diagnostic, clinic-genomic, and harmonized oncologic dataset and database models pertaining to cancer outcome predictions and treatment recommendations; Educational services, namely, conducting community lectures on cancer and related health issues, and distribution of related informational materials therewith; Educational services, namely, conducting classes, seminars, training programs, correspondence courses, and scientific conferences via television, radio, and global computer networks, all in the fields of medicine and biomedical sciences.

Charitable fundraising services by means of raising money for cancer research, cancer treatment, cancer awareness and the construction of facilities for use in cancer research, cancer treatment and cancer awareness.

Research in the biomedical sciences fields, including molecular biology, cell biology, genetics, and immunology; medical services; Healthcare services for treating cancer; Hospital services, namely, patient treatment and care; Pharmaceutical prescription formulation being compounding, and dispensing services; Providing medical services in the nature of patient consultations and medical information via telemedicine; Medical initiative and research and development services pertaining to the development of cancer vaccines that target neoantigens; Scientific research services in the biomedical sciences fields, including molecular biology, cell biology, genetics, and immunology; Compiling medical data for research purposes in the field of gene mutations in rare and common cancers for evaluation and assessing tumor biology, prognosis, and treatment and patient drug response; Providing non-downloadable on-line software, software applications, software tools, and databases using natural language processing and machine learning algorithms, for extracting, characterizing, defining, annotating, curating, structuring, and communicating clinical information and health records; compiling medical data for research purposes.

Medical services; Healthcare services for treating cancer; Hospital services, namely, patient treatment and care; pharmaceutical prescription formulation being compounding, and dispensing services; providing medical services in the nature of patient health consultations for patients and providing medical information via telemedicine, videoconferencing, and teleconferencing software

Filing History

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Feb 13, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Feb 13, 2026 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 9, 2025 GNRN
NON-FINAL ACTION E-MAILED
Dec 9, 2025 GNRT
NON-FINAL ACTION WRITTEN
Dec 9, 2025 CNRT
ASSIGNED TO EXAMINER
Dec 2, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 18, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
Jul 14, 2025 MAFR
NEW APPLICATION ENTERED
Jul 14, 2025 NWAP